TRPA1 promotes cisplatin-induced acute kidney injury by regulating the endoplasmic reticulum stress-mitochondrial damage

Fei Deng, Heping Zhang, Wei Zhou, Shijie Ma, Yuwei Kang, Wei Yang, Liangbin Zhao, Wei QinResearch Square 2023 · DOI

Abstract

Cisplatin (DDP) is a potent chemotherapeutic agent whose clinical use is limited by nephrotoxicity, often leading to acute kidney injury (AKI). This study investigates the role of the Transient Receptor Potential Ankyrin-1 (TRPA1) ion channel in mediating DDP-induced AKI. Using both in vivo mouse models and in vitro HK-2 cell models, researchers found that TRPA1 activation promotes endoplasmic reticulum (ER) stress and mitochondrial damage. Specifically, TRPA1 facilitates calcium overload through mitochondria-associated endoplasmic reticulum membranes (MAMs), leading to mitochondrial dysfunction and apoptosis. Inhibition of TRPA1 with HC-030031 or targeting the tethering protein GRP75 significantly mitigated these effects, suggesting TRPA1 as a potential therapeutic target for preventing cisplatin-induced nephrotoxicity.

Introduction

Cisplatin remains a cornerstone of cancer treatment, yet its effectiveness is frequently compromised by its side effects, most notably acute kidney injury (AKI). Approximately 20–30% of patients undergoing cisplatin therapy experience significant renal impairment. While oxidative stress and apoptosis are known contributors, the precise molecular mechanisms coordinating organelle failure—specifically the crosstalk between the endoplasmic reticulum (ER) and mitochondria—have remained elusive.

This research focuses on the Transient Receptor Potential Ankyrin-1 (TRPA1), a non-selective cation channel. The study explores how TRPA1 acts as a molecular "bridge" that facilitates destructive signaling between the ER and mitochondria, ultimately leading to renal cell death.

Methods

The study utilized a dual-model approach to dissect the pathways involved:

  • In Vivo Model: Male C57BL/6 mice were administered cisplatin to induce AKI. A subset of these mice was treated with the TRPA1 antagonist HC-030031 to evaluate its protective potential.
  • In Vitro Model: Human renal tubular epithelial (HK-2) cells were used for detailed molecular analysis, including the use of TRPA1 agonists (AITC), ER stress inhibitors (4-PBA), and GRP75 inhibitors (MKT077).

Key experimental techniques included Transmission Electron Microscopy (TEM) to visualize Mitochondria-Associated Endoplasmic Reticulum Membranes (MAMs), Western blotting for protein expression, and flow cytometry to measure calcium concentrations and mitochondrial membrane potential.

Table 1: Reagents and resources used in the study, including specific antibodies for ER stress and mitochondrial dynamics markers.

Key Insights: The MAM and Calcium Overload

The study identifies the physical contact points between the ER and mitochondria, known as MAMs, as the primary site of damage. TRPA1 activation leads to an upregulation of GRP75, a protein that tethers the two organelles. This tethering facilitates a massive transfer of calcium from the ER directly into the mitochondria.

This calcium overload triggers a cascade of failure:

  1. Mitochondrial Dysfunction: Loss of membrane potential and decreased ATP production.
  2. Oxidative Stress: A significant spike in Reactive Oxygen Species (ROS).
  3. Dynamic Imbalance: A shift toward mitochondrial fission (fragmentation) mediated by increased p-DRP1 and MFF, and decreased fusion proteins like MFN1 and MFN2.

Results

The experimental results demonstrated that inhibiting TRPA1 provides robust protection against cisplatin-induced damage:

  • Renal Function: In mice, HC-030031 significantly lowered serum creatinine (Scr) and blood urea nitrogen (BUN) levels ($P < 0.001$).
  • Cellular Preservation: TEM imaging showed that TRPA1 inhibition prevented the mitochondrial swelling and ER expansion typically seen after cisplatin exposure.
  • Apoptosis: TUNEL staining confirmed a drastic reduction in apoptotic cells in kidney tissues when TRPA1 was inhibited.
  • Protein Regulation: TRPA1 inhibition successfully downregulated ER stress markers (GRP78, CHOP) and restored the balance of mitochondrial fusion/fission proteins.

Conclusion

The study establishes a clear TRPA1-ERS-Mitochondria axis in the pathogenesis of cisplatin-induced AKI. By regulating the MAM-mediated calcium flux, TRPA1 serves as a critical driver of organelle dysfunction and subsequent renal cell death. These findings highlight TRPA1 as a promising pharmacological target for "reno-protective" strategies, potentially allowing for more aggressive cisplatin dosing in cancer patients while minimizing the risk of life-threatening kidney injury.

Summary updated

Abstract

<title>Abstract</title> Background Cisplatin (DDP) is a widely used and effective chemotherapeutic agent against cancer. However, nephrotoxicity is one of the most common side effects of DDP, and it can proceed to acute kidney injury (AKI). The aim of this study was to investigate the mechanism of TRPA1 in promoting DDP-induced AKI through modulation of the endoplasmic reticulum stress (ERS)-mitochondrial damage. Methods A DDP-induced HK-2 cell model in vitro and mouse model in vivo were established and treated with the TRPA1 antagonist (HC-030031). We also used TRPA1 agonists, and treated with ERS inhibitors or GRP75 inhibitors. Renal function, histopathological changes, apoptosis, ERS and mitochondria-related proteins expression, mitochondrial changes, calcium ion concentration, cell proliferative activity, mitochondrial membrane potential (MMP), ATP, and ROS levels were also evaluated. Result DDP increased Scr and BUN levels, caused renal tissue injury and cell apoptosis, decreased ERS-related proteins GRP78, CHOP, and GRP75. The mitochondrial fusion-related proteins OPA1, MFN1, and MFN2, and mitochondrial division-related proteins p-DRP1 and MFF were elevated, DDP lead to mitochondrial dysfunction, and increased calcium ion concentration. In addition, DDP inhibited cell proliferation activity, decreased MMP and ATP levels, and increased ROS levels. In contrast, HC-030031 had protective effects against DDP-induced ERS and mitochondrial dysfunction<italic>in vivo</italic>and<italic>in vitro</italic>. Futhermore, TRPA1 agonists promoted mitochondrial dysfunction via mitochondria-associated endoplasmic reticulum membrane. ERS inhibitors and GRP75 inhibitors increased cell proliferation activity, reduced cell apoptosis, and modulated ERS-mitochondrial damage and calcium overload to improve cell injury. Conclusion TRPA1 promotes DDP-induced AKI by regulating the ERS-mitochondrial damage.
BibTeX
@inproceedings{deng2023trpa,
  author = {Fei Deng and Heping Zhang and Wei Zhou and Shijie Ma and Yuwei Kang and Wei Yang and Liangbin Zhao and Wei Qin},
  title = {{TRPA1 promotes cisplatin-induced acute kidney injury by regulating the endoplasmic reticulum stress-mitochondrial damage}},
  booktitle = {Research Square},
  year = {2023},
  doi = {10.21203/rs.3.rs-2921017/v1},
}
Figure